𝔖 Bobbio Scriptorium
✦   LIBER   ✦

W1089 Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease

✍ Scribed by Colombel, Jean-Frederic; Rutgeerts, Paul; Sandborn, William J.; Rutgeerts, Paul J.; Hanauer, Stephen B.; Reinisch, Walter; Pollack, Paul F.; Kent, Jeffrey D.; Cardoso, Alexandra T.; Lau, Winnie


Book ID
122918404
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
156 KB
Volume
136
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Adalimumab safety in global clinical tri
✍ Jean-FrΓ©dΓ©ric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 145 KB πŸ‘ 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr